CAG方案治疗中高危骨髓增生异常综合征和急性髓系白血病疗效观察

Clinical observation of the efficacy of CAG regimen for the treatment of intermediate or high risk myelodysplastic syndrome and acute myeloid leukemia

目的观察阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子联合方案（CAG方案）治疗中、高危骨髓增生异常综合征（MDS）和初治急性髓系白血病（AML）的临床疗效及不良反应。方法应用CAG方案治疗中高危MDS28例和AML20例，完成1个疗程后评估疗效，治疗失败患者退出观察，有效者继续接受1个疗程治疗，并进行评估。结果28例MDS临床总有效率53％，其中完全缓解15例（53％），部分缓解0例。AML临床总有效13例（65％），其中完全缓解10例（50％），部分缓解3例（15％）。大部分患者出现了可以耐受的轻微不良反应，主要表现为骨髓抑制。结论CAG治疗中、高危MDS和预后差的AML安全有效，长期疗效需进一步观察。

Objective To observe the efficacy and adverse reactions of CAG regimen （ cytarabine and aclarubicin in combination with granulocyte colony- stimulating factor） for treatment of intermediate or high risk myelodysplastic syndrome （MDS） and acute myeloid leukemia （AML）. Methods Twenty - eight MDS patients and twenty AML patients received CAG regimen. Then, the resulting efficacy was evaluated after one course of treatment, in which those with positive response was given another course of treatment. Results MDS patients presented 53% of clinical effectiveness, including 15 cases （53 % ） with completely remission （CR）. AML patients presented 65 % of clinical effectiveness, including 10 cases （50%） with CR and 3 cases （15%） with partial remission （PR）. Most patients reported slight/mild adverse events, mainly myelosuppression, which was tolerable. Conclusion CAG regimen is safe and effective to treat intermediate or high risk MDS and AML with poor prognosis, and its long - term efficacy requires further observation.